Stifel Nicolaus lowered its price target on Altria Group (MO) by $4 to $68, citing higher-than-expected operating costs. Despite near-term headwinds, the firm reaffirmed its Buy rating, pointing to the tobacco giant's resilient dividend profile and long-term earnings guidance.
Eli Lilly's CEO sees Medicare's new policy covering obesity treatments as a pivotal moment, poised to unlock access for millions of beneficiaries to its incoming oral drug, orforglipron, and intensify the market battle with Novo Nordisk.
The Walt Disney Company exceeded Wall Street expectations in its fiscal first quarter, delivering robust results across its entertainment, experiences, and streaming divisions as longtime CEO Bob Iger prepares to hand over the reins later this year.
Amid a resilient but mixed market, companies with significant insider ownership are drawing investor attention. We examine three firms—spanning crypto, consumer staples, and finance—where management's substantial equity stakes align with ambitious earnings growth forecasts of up to 124%.
A staggering 2,313% surge in Elong Power Holding's (NASDAQ: ELPW) share price last week delivered a massive payoff for its largest shareholder group—private equity firms. With concentrated ownership and scant analyst coverage, the stock's dramatic move highlights both its potential and the risks inherent in such thinly followed names.
In Zimbabwe, where formal employment is scarce and medical costs are prohibitive, a stark financial choice is being made: affordable funeral policies are vastly outpacing health insurance, reflecting a cultural prioritization of dignified burials over accessible healthcare.
The Walt Disney Company reported a 5% rise in fiscal first-quarter revenue to $26 billion, fueled by its theme parks and streaming services. However, operating profit fell 9% as challenges in its traditional TV business and rising costs offset gains.
A new financial analysis suggests shares of the documentary-focused streaming service CuriosityStream may be trading significantly below their estimated intrinsic value, presenting a potential opportunity for investors.
While Vidhance (FRA:8W50) continues to operate at a loss, its current cash reserves and manageable burn rate suggest the company has time to execute its growth strategy. However, a recent dip in revenue adds a note of caution for investors.
While investors chase AI and big tech, a niche biotech firm focused on rare genetic obesity disorders has quietly delivered staggering returns, with Wall Street seeing further 40% upside. Rhythm Pharmaceuticals' targeted approach and upcoming catalysts have analysts bullish, despite its relative anonymity.
Shares of NovaGold Resources (TSX:NG) have tumbled roughly 20% in the past week, reigniting debate over the gold developer's premium valuation. While long-term shareholders have seen stellar returns, the recent pullback forces a fresh look at the risks and rewards priced into its ambitious Donlin project.
Apollo Global Management is deploying billions into AI data center infrastructure and European logistics real estate, underscoring a strategic shift towards hard assets tied to technological transformation and supply chain resilience.
With a cash reserve that could last just over a year at its current burn rate, InflaRx faces a critical period to prove its clinical pipeline's value. While management has reined in spending, the company's financial strategy is now under the microscope.
While market volatility tests many sectors, Hilton Worldwide Holdings has charted a remarkable course. Shareholders have seen total returns near 169% over five years, a performance fueled by a return to profitability and strategic execution that outpaced broader market trends.
Profitability alone doesn't guarantee a stock's success. We examine three companies with strong margins, highlighting two that are leveraging their financial health for growth and one where challenges may cloud the future.
The global packaging giant has successfully completed its court-supervised restructuring, slashing its debt burden by €1.3 billion and securing €349 million in fresh capital to stabilize operations under new ownership led by Redwood Capital Management.
While EyePoint Pharmaceuticals (EYPT) shares have retreated 23% this month, long-term shareholders are still sitting on massive gains. The biotech's 195% three-year surge, despite ongoing losses, highlights a classic market puzzle: balancing current financials with future potential.
While the industrial sector has surged ahead of the broader market, not all companies are equally positioned for sustainable growth. We analyze one defense contractor with strong tailwinds and two manufacturers where valuation concerns loom large.
While the Russell 2000 index is a hunting ground for high-growth potential, its smaller constituents often carry heightened risks. We examine three specific stocks where valuation concerns and business headwinds suggest investors might want to look elsewhere.
The frozen food giant announces a steady quarterly payout, with analysts highlighting a sustainable yield but tempered expectations for future dividend hikes.
